drugset
drugset / Trial / NCT04713319

Novel Energy Metabolic Signaling Molecule With Therapeutic Potential

NCT04713319 ↗

Phase 0 Completed 27 enrolled Petteri Hirvonen University of Jyvaskyla · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

Altogether a 25-day study. First 4 days non-blinded with water before 0-control blood samples (Day0). Thereafter blinded for 21 days (3 weeks). Study group was apparently healthy 50-60 -year-old males and females (N=27).

Timeline

Start
2019-10-04
Primary completion
2021-12-31
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Panavital Unknown 1.665 mg/kg —

Indications

No indication recorded.